Business
Press Release Sep 06 2024
Strides Pharma Science Limited has informed the Exchange regarding a press release dated September 06, 2024, titled "Strides receive USFDA approval for Theophylline Extended-Release Tablets, 300 mg and 450 mg".
About this update from Strides Pharma Science Ltd
Strides Pharma Science Limited has informed the Exchange regarding a press release dated September 06, 2024, titled "Strides receive USFDA approval for Theophylline Extended-Release Tablets, 300 mg and 450 mg". View Attachment
View stock analysis, news, and events for Strides Pharma Science Ltd